These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 29717036)
1. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2. Duffin KC; Papp KA; Bagel J; Levi E; Chen R; Gottlieb AB J Drugs Dermatol; 2017 Feb; 16(2):147-153. PubMed ID: 28300857 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798 [No Abstract] [Full Text] [Related]
5. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life. Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887 [TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302 [TBL] [Abstract][Full Text] [Related]
8. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760 [TBL] [Abstract][Full Text] [Related]
9. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. Gold LS; Hansen JB; Patel D; Veverka KA; Strober B J Am Acad Dermatol; 2020 Jul; 83(1):131-138. PubMed ID: 32430142 [TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol in the treatment of psoriasis: Real-life data. Turkmen M; Dogan S Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940 [TBL] [Abstract][Full Text] [Related]
11. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment. Chow C; Simpson MJ; Luger TA; Chubb H; Ellis CN J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315 [TBL] [Abstract][Full Text] [Related]
12. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Gladman D; Fleischmann R; Coteur G; Woltering F; Mease PJ Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1085-92. PubMed ID: 24339179 [TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928 [No Abstract] [Full Text] [Related]
14. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699 [TBL] [Abstract][Full Text] [Related]
15. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Kavanaugh A; Gladman D; van der Heijde D; Purcaru O; Mease P Ann Rheum Dis; 2015 Jan; 74(1):44-51. PubMed ID: 24942382 [TBL] [Abstract][Full Text] [Related]
16. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers. Vender RB; Lynde CW J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313 [TBL] [Abstract][Full Text] [Related]
17. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. Torii H; Nakagawa H; J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039 [TBL] [Abstract][Full Text] [Related]
18. [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol. Ruiz AN; Alberola FT; Aceituno S; Farm Hosp; 2024; 48(2):T51-T56. PubMed ID: 38148255 [TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Gordon KB; Warren RB; Gottlieb AB; Blauvelt A; Thaçi D; Leonardi C; Poulin Y; Boehnlein M; Brock F; Ecoffet C; Reich K Br J Dermatol; 2021 Apr; 184(4):652-662. PubMed ID: 32652544 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]